Saluda Medical Stock Forecast

Stock Price Forecast

According to 2 analysts polled by S&P Global, Saluda Medical stock has a consensus rating of "Strong Buy" and an average price target of $2.51. The average 1-year stock price forecast is 504.82% higher than the current stock price, while the lowest is $2.03 (+389.16%) and the highest is $2.99 (+620.48%).

Price Target: $2.51 (+504.82%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$2.03	$2.51	$2.51	$2.99
Change	+389.16%	+504.82%	+504.82%	+620.48%

Analyst Ratings

The average analyst rating for Saluda Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Apr '26	May '26
Strong Buy	1	1	2	2	2
Buy	0	0	0	0	0
Hold	0	0	0	0	0
Sell	0	0	0	0	0
Strong Sell	0	0	0	0	0
Total	1	1	2	2	2

Financial Forecast

Revenue This Year

87.41M

from 70.36M

24.24%

from 70.36M

Revenue Next Year

127.08M

from 87.41M

45.38%

from 87.41M

EPS This Year

-0.48

from -

EPS Next Year

-0.37

from -0.48

Fiscal Year	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Jun 30, 2023	Jun 30, 2024	Jun 30, 2025	Jun 30, 2026
Revenue	22.23M	51.68M	70.36M	87.41M
Revenue Growth	-	132.45%	36.13%	24.24%
Gross Profit	4.04M	23.11M	32.76M	41.26M
Gross Margin	18.17%	44.72%	46.56%	47.20%
Operating Income	-92.22M	-99.14M	-118.05M	-134.59M
Net Income	-92.16M	-97.83M	-149.30M	-142.50M
EPS	-	-	-	-0.48
Free Cash Flow	-	-71.68M	-67.53M	-119.20M
No. Analysts	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	87.8M
Avg	87.4M
Low	87.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	24.8%
Avg	24.2%
Low	23.7%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.48
Low	-

EPS Growth

EPS Growth	2027	2028
High	-
Avg	-
Low	-